| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombotic Thrombocytopenic | 124 | 2024 | 216 | 30.370 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 52 | 2021 | 94 | 10.230 |
Why?
|
| Thrombocytopenia | 39 | 2022 | 113 | 9.030 |
Why?
|
| Hemolytic-Uremic Syndrome | 44 | 2015 | 81 | 8.370 |
Why?
|
| Plasma Exchange | 58 | 2022 | 104 | 7.280 |
Why?
|
| Registries | 39 | 2021 | 398 | 6.870 |
Why?
|
| ADAMTS13 Protein | 68 | 2024 | 126 | 6.420 |
Why?
|
| ADAM Proteins | 52 | 2023 | 103 | 6.260 |
Why?
|
| Thrombotic Microangiopathies | 12 | 2018 | 24 | 5.390 |
Why?
|
| Humans | 237 | 2024 | 29078 | 3.670 |
Why?
|
| Pregnancy Complications, Hematologic | 20 | 2021 | 38 | 3.550 |
Why?
|
| Platelet Count | 31 | 2021 | 111 | 3.540 |
Why?
|
| Rituximab | 21 | 2020 | 64 | 3.100 |
Why?
|
| Female | 138 | 2024 | 15740 | 2.750 |
Why?
|
| Adult | 106 | 2024 | 8080 | 2.720 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 10 | 2018 | 67 | 2.560 |
Why?
|
| Quinine | 8 | 2017 | 23 | 2.420 |
Why?
|
| Pregnancy | 35 | 2024 | 1261 | 2.250 |
Why?
|
| Stroke | 5 | 2022 | 261 | 2.160 |
Why?
|
| Male | 104 | 2022 | 14049 | 2.080 |
Why?
|
| Recurrence | 32 | 2022 | 328 | 2.060 |
Why?
|
| Blood Platelets | 19 | 2022 | 206 | 1.820 |
Why?
|
| Oklahoma | 34 | 2018 | 1062 | 1.810 |
Why?
|
| Receptors, Fc | 8 | 2013 | 31 | 1.800 |
Why?
|
| Splenectomy | 18 | 2019 | 44 | 1.720 |
Why?
|
| Middle Aged | 72 | 2021 | 7458 | 1.710 |
Why?
|
| von Willebrand Factor | 16 | 2023 | 36 | 1.710 |
Why?
|
| Thrombopoietin | 10 | 2013 | 17 | 1.710 |
Why?
|
| Anemia, Hemolytic | 6 | 2021 | 22 | 1.670 |
Why?
|
| Immunologic Factors | 6 | 2019 | 50 | 1.660 |
Why?
|
| Autoantibodies | 13 | 2018 | 486 | 1.640 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 13 | 2015 | 42 | 1.520 |
Why?
|
| Child | 34 | 2022 | 2335 | 1.470 |
Why?
|
| Immunosuppressive Agents | 20 | 2020 | 151 | 1.460 |
Why?
|
| Adrenal Cortex Hormones | 15 | 2019 | 75 | 1.430 |
Why?
|
| Recombinant Fusion Proteins | 8 | 2013 | 233 | 1.400 |
Why?
|
| Diagnosis, Differential | 23 | 2023 | 379 | 1.390 |
Why?
|
| Metalloendopeptidases | 11 | 2005 | 40 | 1.360 |
Why?
|
| Aged | 44 | 2021 | 5627 | 1.340 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2012 | 84 | 1.310 |
Why?
|
| Adolescent | 36 | 2021 | 3233 | 1.300 |
Why?
|
| Depression | 3 | 2018 | 229 | 1.290 |
Why?
|
| Quality of Life | 9 | 2016 | 523 | 1.290 |
Why?
|
| Treatment Outcome | 31 | 2024 | 2430 | 1.190 |
Why?
|
| Single-Domain Antibodies | 5 | 2021 | 7 | 1.150 |
Why?
|
| Autoimmune Diseases | 8 | 2019 | 170 | 1.060 |
Why?
|
| Muscle Relaxants, Central | 4 | 2017 | 11 | 0.920 |
Why?
|
| Young Adult | 19 | 2022 | 2855 | 0.910 |
Why?
|
| Mutation | 6 | 2023 | 873 | 0.900 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2021 | 20 | 0.900 |
Why?
|
| Hematology | 8 | 2019 | 25 | 0.880 |
Why?
|
| Neoplasms | 7 | 2016 | 882 | 0.840 |
Why?
|
| Diagnostic Errors | 5 | 2017 | 32 | 0.840 |
Why?
|
| Platelet Transfusion | 8 | 2013 | 29 | 0.820 |
Why?
|
| Glucocorticoids | 10 | 2019 | 115 | 0.810 |
Why?
|
| Child, Preschool | 16 | 2021 | 1201 | 0.800 |
Why?
|
| Blood Component Transfusion | 2 | 2021 | 13 | 0.790 |
Why?
|
| Anemia, Sickle Cell | 2 | 2022 | 39 | 0.780 |
Why?
|
| Infant, Newborn | 13 | 2022 | 924 | 0.770 |
Why?
|
| Acute Kidney Injury | 4 | 2017 | 74 | 0.730 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 538 | 0.700 |
Why?
|
| Follow-Up Studies | 13 | 2014 | 1033 | 0.690 |
Why?
|
| Diarrhea | 6 | 2017 | 57 | 0.690 |
Why?
|
| Infant | 11 | 2022 | 1056 | 0.680 |
Why?
|
| Hemorrhage | 10 | 2012 | 266 | 0.670 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 249 | 0.670 |
Why?
|
| Cognition Disorders | 2 | 2015 | 186 | 0.650 |
Why?
|
| Carrier Proteins | 5 | 2009 | 256 | 0.650 |
Why?
|
| Hypertension, Pulmonary | 2 | 2022 | 34 | 0.630 |
Why?
|
| Receptors, Thrombopoietin | 4 | 2014 | 8 | 0.620 |
Why?
|
| Jehovah's Witnesses | 1 | 2019 | 5 | 0.610 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 6 | 0.610 |
Why?
|
| Pregnancy Complications | 3 | 2018 | 112 | 0.590 |
Why?
|
| Purpura, Thrombocytopenic | 4 | 2008 | 6 | 0.590 |
Why?
|
| Antibodies, Monoclonal | 7 | 2013 | 336 | 0.590 |
Why?
|
| Eclampsia | 2 | 2017 | 5 | 0.580 |
Why?
|
| Puerperal Disorders | 2 | 2017 | 14 | 0.570 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 413 | 0.570 |
Why?
|
| Transplantation, Homologous | 4 | 2008 | 48 | 0.560 |
Why?
|
| HIV Infections | 2 | 2012 | 165 | 0.560 |
Why?
|
| Databases, Factual | 4 | 2013 | 271 | 0.560 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 136 | 0.560 |
Why?
|
| Placenta | 1 | 2018 | 78 | 0.550 |
Why?
|
| Cognitive Dysfunction | 2 | 2018 | 271 | 0.540 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2015 | 9 | 0.540 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 6 | 0.530 |
Why?
|
| Judgment | 1 | 2017 | 31 | 0.530 |
Why?
|
| Evidence-Based Medicine | 4 | 2015 | 148 | 0.530 |
Why?
|
| Risk Factors | 13 | 2014 | 2138 | 0.530 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 50 | 0.520 |
Why?
|
| Cohort Studies | 9 | 2016 | 902 | 0.520 |
Why?
|
| Recombinant Proteins | 6 | 2024 | 417 | 0.520 |
Why?
|
| Kidney Failure, Chronic | 4 | 2017 | 70 | 0.520 |
Why?
|
| Combined Modality Therapy | 11 | 2016 | 303 | 0.520 |
Why?
|
| Prednisone | 10 | 2014 | 54 | 0.520 |
Why?
|
| Plasma | 3 | 2022 | 32 | 0.510 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 351 | 0.500 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2017 | 59 | 0.500 |
Why?
|
| Patient Selection | 1 | 2017 | 151 | 0.500 |
Why?
|
| Interferons | 1 | 2016 | 70 | 0.490 |
Why?
|
| Pre-Eclampsia | 3 | 2014 | 49 | 0.490 |
Why?
|
| Terminology as Topic | 4 | 2009 | 64 | 0.490 |
Why?
|
| International Classification of Diseases | 3 | 2012 | 38 | 0.480 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2013 | 997 | 0.480 |
Why?
|
| Retrospective Studies | 10 | 2019 | 2651 | 0.470 |
Why?
|
| Drug Hypersensitivity | 3 | 2016 | 23 | 0.470 |
Why?
|
| Prevalence | 4 | 2022 | 523 | 0.470 |
Why?
|
| Blood Platelet Disorders | 3 | 2004 | 10 | 0.460 |
Why?
|
| Heart Diseases | 3 | 2016 | 71 | 0.450 |
Why?
|
| Survival Rate | 5 | 2018 | 433 | 0.450 |
Why?
|
| United States | 14 | 2024 | 2252 | 0.440 |
Why?
|
| Population Surveillance | 2 | 2012 | 87 | 0.440 |
Why?
|
| Back Pain | 1 | 2014 | 21 | 0.430 |
Why?
|
| Drug Therapy, Combination | 5 | 2019 | 210 | 0.430 |
Why?
|
| Syndrome | 6 | 2016 | 79 | 0.430 |
Why?
|
| Necrosis | 1 | 2014 | 85 | 0.420 |
Why?
|
| Albuminuria | 1 | 2014 | 23 | 0.420 |
Why?
|
| Escherichia coli Infections | 3 | 2012 | 45 | 0.420 |
Why?
|
| Acetylcysteine | 1 | 2014 | 24 | 0.420 |
Why?
|
| Sepsis | 3 | 2012 | 88 | 0.420 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 43 | 0.420 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 7 | 0.410 |
Why?
|
| Prospective Studies | 11 | 2014 | 1286 | 0.410 |
Why?
|
| Eye Hemorrhage | 1 | 2013 | 1 | 0.410 |
Why?
|
| Thrombocytopenia, Neonatal Alloimmune | 1 | 2013 | 1 | 0.410 |
Why?
|
| Escherichia coli O157 | 3 | 2009 | 24 | 0.410 |
Why?
|
| Incidence | 7 | 2015 | 574 | 0.400 |
Why?
|
| Cyclosporine | 5 | 2008 | 23 | 0.400 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 127 | 0.400 |
Why?
|
| Recovery of Function | 1 | 2014 | 123 | 0.400 |
Why?
|
| African Americans | 4 | 2011 | 353 | 0.400 |
Why?
|
| Conflict of Interest | 1 | 2013 | 17 | 0.390 |
Why?
|
| Sex Factors | 5 | 2018 | 473 | 0.390 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 101 | 0.380 |
Why?
|
| Fatal Outcome | 5 | 2017 | 69 | 0.380 |
Why?
|
| Isoantibodies | 5 | 2013 | 15 | 0.370 |
Why?
|
| Aged, 80 and over | 13 | 2012 | 2070 | 0.370 |
Why?
|
| Medical Records | 1 | 2012 | 52 | 0.370 |
Why?
|
| Seasons | 1 | 2012 | 94 | 0.360 |
Why?
|
| Thrombopoiesis | 2 | 2008 | 6 | 0.350 |
Why?
|
| Chronic Disease | 8 | 2022 | 274 | 0.350 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 468 | 0.340 |
Why?
|
| Dexamethasone | 2 | 2018 | 63 | 0.340 |
Why?
|
| Research Personnel | 2 | 2015 | 40 | 0.330 |
Why?
|
| Cyclophosphamide | 2 | 2018 | 43 | 0.330 |
Why?
|
| Prognosis | 7 | 2016 | 815 | 0.330 |
Why?
|
| Remission Induction | 7 | 2020 | 58 | 0.330 |
Why?
|
| Bone Marrow | 5 | 2022 | 83 | 0.320 |
Why?
|
| Epitopes | 2 | 2009 | 185 | 0.320 |
Why?
|
| Piperacillin | 1 | 2010 | 2 | 0.320 |
Why?
|
| Review Literature as Topic | 2 | 2014 | 10 | 0.310 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2008 | 45 | 0.310 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 40 | 0.310 |
Why?
|
| Morbidity | 3 | 2022 | 60 | 0.300 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 236 | 0.300 |
Why?
|
| Graft vs Host Disease | 3 | 2008 | 32 | 0.300 |
Why?
|
| Pharmaceutical Preparations | 2 | 2010 | 49 | 0.290 |
Why?
|
| Predictive Value of Tests | 5 | 2016 | 485 | 0.290 |
Why?
|
| Platelet Aggregation | 3 | 2005 | 44 | 0.290 |
Why?
|
| Platelet Membrane Glycoproteins | 4 | 2000 | 13 | 0.280 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2009 | 37 | 0.280 |
Why?
|
| Disease Management | 7 | 2021 | 91 | 0.280 |
Why?
|
| Memory | 1 | 2008 | 76 | 0.280 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2018 | 177 | 0.280 |
Why?
|
| Physical Endurance | 1 | 2008 | 91 | 0.270 |
Why?
|
| Beverages | 3 | 2016 | 24 | 0.270 |
Why?
|
| Attention | 1 | 2008 | 91 | 0.270 |
Why?
|
| Enterocolitis | 1 | 2007 | 5 | 0.270 |
Why?
|
| Biomarkers | 6 | 2016 | 787 | 0.270 |
Why?
|
| Age Factors | 5 | 2013 | 740 | 0.270 |
Why?
|
| Pentostatin | 2 | 2015 | 4 | 0.270 |
Why?
|
| Liver Cirrhosis | 1 | 2008 | 78 | 0.260 |
Why?
|
| Immunoglobulin G | 3 | 2006 | 276 | 0.260 |
Why?
|
| Community Health Services | 1 | 2007 | 34 | 0.260 |
Why?
|
| Pancreatitis | 1 | 2007 | 36 | 0.260 |
Why?
|
| Nephrectomy | 1 | 2007 | 48 | 0.260 |
Why?
|
| Rho(D) Immune Globulin | 6 | 2013 | 12 | 0.250 |
Why?
|
| Research Design | 4 | 2017 | 188 | 0.250 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 72 | 0.250 |
Why?
|
| Iron Overload | 1 | 2006 | 3 | 0.240 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 221 | 0.240 |
Why?
|
| Megakaryocytes | 2 | 2012 | 30 | 0.240 |
Why?
|
| Bone Marrow Transplantation | 3 | 2007 | 49 | 0.240 |
Why?
|
| Erythrocyte Transfusion | 1 | 2006 | 15 | 0.240 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2017 | 35 | 0.240 |
Why?
|
| Vascular Diseases | 2 | 2022 | 68 | 0.230 |
Why?
|
| Liver Diseases | 1 | 2006 | 52 | 0.230 |
Why?
|
| Public Sector | 1 | 2005 | 3 | 0.230 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 12 | 0.230 |
Why?
|
| Plasmapheresis | 2 | 2005 | 6 | 0.230 |
Why?
|
| Antineoplastic Agents | 6 | 2016 | 686 | 0.230 |
Why?
|
| Immunoglobulins, Intravenous | 5 | 2018 | 16 | 0.230 |
Why?
|
| Thrombosis | 2 | 2022 | 150 | 0.220 |
Why?
|
| Publishing | 1 | 2005 | 34 | 0.220 |
Why?
|
| Heterozygote | 2 | 2019 | 69 | 0.220 |
Why?
|
| Awards and Prizes | 1 | 2004 | 9 | 0.220 |
Why?
|
| Thiamine | 2 | 2022 | 6 | 0.220 |
Why?
|
| Age Distribution | 3 | 2013 | 75 | 0.220 |
Why?
|
| Surveys and Questionnaires | 11 | 2018 | 1015 | 0.210 |
Why?
|
| Benchmarking | 1 | 2004 | 33 | 0.210 |
Why?
|
| Reference Values | 3 | 2018 | 200 | 0.210 |
Why?
|
| Blood Chemical Analysis | 1 | 2004 | 17 | 0.210 |
Why?
|
| Vancomycin | 2 | 2015 | 59 | 0.210 |
Why?
|
| History, 20th Century | 2 | 2019 | 85 | 0.200 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 18 | 0.200 |
Why?
|
| HELLP Syndrome | 3 | 2015 | 5 | 0.200 |
Why?
|
| Time Factors | 5 | 2009 | 1619 | 0.200 |
Why?
|
| Clinical Protocols | 3 | 2017 | 46 | 0.200 |
Why?
|
| Hemoglobins | 2 | 2018 | 118 | 0.200 |
Why?
|
| Catheterization, Central Venous | 4 | 2012 | 38 | 0.190 |
Why?
|
| Boidae | 1 | 2002 | 2 | 0.190 |
Why?
|
| Antirheumatic Agents | 1 | 2003 | 57 | 0.190 |
Why?
|
| Disease Progression | 3 | 2015 | 481 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2002 | 6 | 0.190 |
Why?
|
| Salmonella enterica | 1 | 2002 | 9 | 0.190 |
Why?
|
| Salmonella Infections | 1 | 2002 | 18 | 0.190 |
Why?
|
| Hypertension | 3 | 2012 | 309 | 0.180 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 79 | 0.180 |
Why?
|
| Medical Oncology | 3 | 2014 | 99 | 0.180 |
Why?
|
| Drug Administration Schedule | 5 | 2013 | 225 | 0.180 |
Why?
|
| Risk | 3 | 2012 | 138 | 0.180 |
Why?
|
| Cognition | 3 | 2010 | 331 | 0.180 |
Why?
|
| Vaccines | 1 | 2022 | 37 | 0.180 |
Why?
|
| Renal Dialysis | 2 | 2017 | 53 | 0.170 |
Why?
|
| Ticlopidine | 1 | 2001 | 34 | 0.170 |
Why?
|
| Cause of Death | 2 | 2013 | 73 | 0.170 |
Why?
|
| Antibodies | 4 | 2015 | 125 | 0.160 |
Why?
|
| Decision Making | 3 | 2018 | 179 | 0.160 |
Why?
|
| Autoimmunity | 1 | 2021 | 158 | 0.160 |
Why?
|
| Genes, Recessive | 1 | 2019 | 21 | 0.160 |
Why?
|
| Antilymphocyte Serum | 1 | 1999 | 4 | 0.160 |
Why?
|
| Sezary Syndrome | 1 | 1999 | 1 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2000 | 114 | 0.150 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 90 | 0.150 |
Why?
|
| Autoantigens | 2 | 2012 | 216 | 0.150 |
Why?
|
| Data Collection | 2 | 2017 | 109 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 18 | 0.150 |
Why?
|
| Food | 2 | 2010 | 32 | 0.150 |
Why?
|
| Homozygote | 1 | 2019 | 36 | 0.150 |
Why?
|
| Steroids | 1 | 2019 | 58 | 0.150 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2007 | 21 | 0.150 |
Why?
|
| Treatment Failure | 2 | 2014 | 76 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2018 | 6 | 0.150 |
Why?
|
| Trimethoprim | 1 | 2018 | 6 | 0.150 |
Why?
|
| Enzyme Activation | 3 | 2016 | 267 | 0.150 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 131 | 0.150 |
Why?
|
| Mycophenolic Acid | 1 | 2018 | 18 | 0.150 |
Why?
|
| Chorionic Villi | 1 | 2018 | 7 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2018 | 15 | 0.150 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 14 | 0.150 |
Why?
|
| Flavonoids | 1 | 2018 | 33 | 0.140 |
Why?
|
| Warfarin | 1 | 2019 | 94 | 0.140 |
Why?
|
| Capillaries | 1 | 2018 | 33 | 0.140 |
Why?
|
| Fetal Blood | 1 | 2018 | 40 | 0.140 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2018 | 18 | 0.140 |
Why?
|
| Anticonvulsants | 1 | 2018 | 20 | 0.140 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 26 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 55 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 251 | 0.140 |
Why?
|
| Specialization | 2 | 2018 | 19 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 20 | 0.140 |
Why?
|
| Alleles | 1 | 2019 | 357 | 0.140 |
Why?
|
| Secondary Prevention | 2 | 2016 | 46 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 284 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2010 | 740 | 0.130 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 8 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2018 | 120 | 0.130 |
Why?
|
| Animals | 10 | 2022 | 10756 | 0.130 |
Why?
|
| Phenotype | 3 | 2016 | 688 | 0.130 |
Why?
|
| Anuria | 1 | 2017 | 2 | 0.130 |
Why?
|
| Postpartum Period | 1 | 2017 | 79 | 0.130 |
Why?
|
| Blood Urea Nitrogen | 1 | 2017 | 13 | 0.130 |
Why?
|
| Gastroenteritis | 1 | 2017 | 7 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 44 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 484 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 121 | 0.130 |
Why?
|
| Vomiting | 1 | 2017 | 14 | 0.130 |
Why?
|
| Gestational Age | 1 | 2017 | 147 | 0.130 |
Why?
|
| Health Status | 2 | 2008 | 149 | 0.130 |
Why?
|
| Creatinine | 1 | 2017 | 60 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2017 | 35 | 0.130 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 8 | 0.130 |
Why?
|
| Biopsy | 3 | 2022 | 208 | 0.120 |
Why?
|
| Chills | 1 | 2016 | 3 | 0.120 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 177 | 0.120 |
Why?
|
| Nonprescription Drugs | 1 | 2016 | 7 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 612 | 0.120 |
Why?
|
| Causality | 1 | 2016 | 13 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 14 | 0.120 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 6 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 14 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 11 | 0.120 |
Why?
|
| Fever | 1 | 2016 | 31 | 0.120 |
Why?
|
| Blindness | 1 | 2016 | 34 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 47 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2016 | 34 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2016 | 114 | 0.120 |
Why?
|
| Self Report | 1 | 2016 | 122 | 0.120 |
Why?
|
| Prescription Fees | 1 | 2015 | 3 | 0.120 |
Why?
|
| Patient Advocacy | 1 | 2015 | 16 | 0.120 |
Why?
|
| Drug Costs | 1 | 2015 | 17 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 433 | 0.110 |
Why?
|
| Convalescence | 1 | 2015 | 6 | 0.110 |
Why?
|
| Self-Help Groups | 2 | 2007 | 16 | 0.110 |
Why?
|
| Intelligence Tests | 1 | 2015 | 25 | 0.110 |
Why?
|
| Mentors | 1 | 2015 | 39 | 0.110 |
Why?
|
| Erythropoietin | 2 | 2006 | 12 | 0.110 |
Why?
|
| Wisconsin | 1 | 2015 | 9 | 0.110 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 24 | 0.110 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2015 | 2 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 681 | 0.110 |
Why?
|
| Faculty, Medical | 1 | 2015 | 60 | 0.110 |
Why?
|
| Ribosomes | 1 | 2015 | 32 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 55 | 0.110 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2014 | 3 | 0.110 |
Why?
|
| Patient Participation | 1 | 2015 | 58 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 19 | 0.110 |
Why?
|
| Polyethylene | 1 | 2014 | 12 | 0.110 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2014 | 8 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 119 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2015 | 67 | 0.110 |
Why?
|
| Platelet Activation | 5 | 2022 | 55 | 0.110 |
Why?
|
| Health Expenditures | 2 | 2012 | 30 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 48 | 0.100 |
Why?
|
| Obstetrics | 1 | 2015 | 57 | 0.100 |
Why?
|
| Camptothecin | 1 | 2014 | 16 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 93 | 0.100 |
Why?
|
| Outpatients | 2 | 2012 | 44 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 249 | 0.100 |
Why?
|
| Psychometrics | 3 | 2008 | 122 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 54 | 0.100 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 19 | 0.100 |
Why?
|
| Japan | 1 | 2013 | 24 | 0.100 |
Why?
|
| Gene Expression | 1 | 2015 | 417 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 20 | 0.100 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2013 | 4 | 0.100 |
Why?
|
| Mortality | 1 | 2013 | 46 | 0.100 |
Why?
|
| Financial Support | 1 | 2013 | 9 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2013 | 43 | 0.100 |
Why?
|
| Internationality | 1 | 2013 | 32 | 0.100 |
Why?
|
| Elliptocytosis, Hereditary | 1 | 2012 | 2 | 0.100 |
Why?
|
| Meningitis, Bacterial | 1 | 2012 | 9 | 0.090 |
Why?
|
| Individuality | 1 | 2012 | 19 | 0.090 |
Why?
|
| Physicians | 2 | 2014 | 83 | 0.090 |
Why?
|
| Foodborne Diseases | 1 | 2012 | 12 | 0.090 |
Why?
|
| Endocarditis, Bacterial | 1 | 2012 | 15 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2010 | 14 | 0.090 |
Why?
|
| Health Resources | 1 | 2012 | 19 | 0.090 |
Why?
|
| History, 21st Century | 2 | 2019 | 50 | 0.090 |
Why?
|
| Drug Resistance | 2 | 2014 | 42 | 0.090 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2012 | 4 | 0.090 |
Why?
|
| Blood Preservation | 1 | 1992 | 9 | 0.090 |
Why?
|
| Inpatients | 1 | 2012 | 60 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 54 | 0.090 |
Why?
|
| Filgrastim | 1 | 2011 | 7 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2011 | 15 | 0.090 |
Why?
|
| ABO Blood-Group System | 1 | 2011 | 7 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 18 | 0.090 |
Why?
|
| Critical Care | 1 | 2011 | 49 | 0.090 |
Why?
|
| Autopsy | 2 | 2008 | 26 | 0.090 |
Why?
|
| Aspirin | 2 | 2022 | 125 | 0.080 |
Why?
|
| Reproducibility of Results | 6 | 2013 | 788 | 0.080 |
Why?
|
| Bacteremia | 2 | 2010 | 81 | 0.080 |
Why?
|
| Cytoplasmic Granules | 1 | 1990 | 3 | 0.080 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2010 | 1 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2008 | 426 | 0.080 |
Why?
|
| Fatigue | 1 | 2011 | 66 | 0.080 |
Why?
|
| Herbal Medicine | 1 | 2010 | 1 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 1 | 2010 | 10 | 0.080 |
Why?
|
| Current Procedural Terminology | 1 | 2010 | 11 | 0.080 |
Why?
|
| Kuwait | 1 | 2010 | 3 | 0.080 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 11 | 0.080 |
Why?
|
| Age of Onset | 2 | 2021 | 72 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 157 | 0.080 |
Why?
|
| Inflammation | 3 | 2022 | 669 | 0.080 |
Why?
|
| Hemolysis | 2 | 2022 | 51 | 0.080 |
Why?
|
| Immune System Diseases | 2 | 2008 | 4 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 100 | 0.080 |
Why?
|
| Anticoagulants | 3 | 2018 | 297 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2010 | 61 | 0.080 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 18 | 0.080 |
Why?
|
| Helicobacter Infections | 1 | 2009 | 17 | 0.080 |
Why?
|
| Disintegrins | 1 | 2009 | 1 | 0.070 |
Why?
|
| Thrombospondins | 1 | 2009 | 6 | 0.070 |
Why?
|
| Antigens, Human Platelet | 1 | 2009 | 5 | 0.070 |
Why?
|
| Metalloproteases | 1 | 2009 | 7 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 6 | 0.070 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2008 | 18 | 0.070 |
Why?
|
| Fetal Death | 1 | 2008 | 21 | 0.070 |
Why?
|
| International Cooperation | 1 | 2008 | 20 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2008 | 25 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2008 | 14 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 40 | 0.070 |
Why?
|
| Reference Standards | 1 | 2008 | 57 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2009 | 68 | 0.070 |
Why?
|
| Pedigree | 1 | 2008 | 155 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 191 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 58 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2009 | 58 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2009 | 114 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 98 | 0.070 |
Why?
|
| Hepatitis B, Chronic | 1 | 2008 | 6 | 0.070 |
Why?
|
| Switzerland | 1 | 2008 | 6 | 0.070 |
Why?
|
| Heparin | 2 | 2013 | 111 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 2 | 2005 | 20 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 32 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2008 | 202 | 0.070 |
Why?
|
| Genotype | 1 | 2008 | 461 | 0.070 |
Why?
|
| Mice | 3 | 2022 | 4845 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 66 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2007 | 17 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2009 | 169 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2010 | 273 | 0.070 |
Why?
|
| Cholestasis | 1 | 2007 | 13 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2008 | 515 | 0.060 |
Why?
|
| Haptoglobins | 1 | 2007 | 22 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 81 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 176 | 0.060 |
Why?
|
| Epoetin Alfa | 1 | 2006 | 2 | 0.060 |
Why?
|
| Darbepoetin alfa | 1 | 2006 | 2 | 0.060 |
Why?
|
| Phlebotomy | 1 | 2006 | 3 | 0.060 |
Why?
|
| Transferrin | 1 | 2006 | 10 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2006 | 13 | 0.060 |
Why?
|
| Pancreatic Diseases | 1 | 2006 | 13 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2007 | 159 | 0.060 |
Why?
|
| Ferritins | 1 | 2006 | 27 | 0.060 |
Why?
|
| Alcoholism | 1 | 2007 | 122 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2006 | 30 | 0.060 |
Why?
|
| Cytokines | 1 | 2008 | 456 | 0.060 |
Why?
|
| Shiga Toxin 2 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Platelet Adhesiveness | 1 | 2005 | 7 | 0.060 |
Why?
|
| Copyright | 1 | 2005 | 2 | 0.060 |
Why?
|
| Volunteers | 1 | 2005 | 4 | 0.060 |
Why?
|
| Authorship | 1 | 2005 | 14 | 0.060 |
Why?
|
| Interleukin-11 | 2 | 2002 | 6 | 0.050 |
Why?
|
| Injections, Subcutaneous | 2 | 2020 | 60 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 74 | 0.050 |
Why?
|
| Blood Banks | 1 | 2004 | 2 | 0.050 |
Why?
|
| Community Medicine | 1 | 2004 | 9 | 0.050 |
Why?
|
| Drug Industry | 1 | 2024 | 15 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2005 | 109 | 0.050 |
Why?
|
| MEDLINE | 1 | 2004 | 26 | 0.050 |
Why?
|
| Safety | 1 | 2004 | 33 | 0.050 |
Why?
|
| Internet | 1 | 2005 | 129 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 2001 | 31 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 93 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2004 | 78 | 0.050 |
Why?
|
| Research | 1 | 2004 | 93 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 1996 | 198 | 0.050 |
Why?
|
| Universities | 1 | 2004 | 125 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 92 | 0.050 |
Why?
|
| Education, Medical | 1 | 2004 | 68 | 0.050 |
Why?
|
| Comorbidity | 1 | 2004 | 261 | 0.050 |
Why?
|
| Etanercept | 1 | 2003 | 6 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 153 | 0.050 |
Why?
|
| Serotyping | 1 | 2002 | 10 | 0.050 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 4 | 0.050 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2002 | 1 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2002 | 9 | 0.050 |
Why?
|
| Clone Cells | 1 | 2002 | 22 | 0.050 |
Why?
|
| Patient Satisfaction | 3 | 2009 | 97 | 0.050 |
Why?
|
| Neutropenia | 1 | 2002 | 41 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2022 | 15 | 0.050 |
Why?
|
| Analgesics | 1 | 2022 | 39 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2005 | 876 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2022 | 120 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2003 | 136 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2022 | 45 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 82 | 0.040 |
Why?
|
| Mitomycin | 1 | 2001 | 19 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2004 | 631 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 145 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 32 | 0.040 |
Why?
|
| Neutrophils | 1 | 2002 | 185 | 0.040 |
Why?
|
| Histocompatibility | 1 | 2001 | 5 | 0.040 |
Why?
|
| Indians, North American | 2 | 2011 | 545 | 0.040 |
Why?
|
| Aphasia, Broca | 1 | 2001 | 2 | 0.040 |
Why?
|
| Amnesia | 1 | 2001 | 9 | 0.040 |
Why?
|
| Case Management | 1 | 2001 | 11 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 76 | 0.040 |
Why?
|
| Sleep-Wake Transition Disorders | 1 | 2000 | 1 | 0.040 |
Why?
|
| Headache | 1 | 2001 | 35 | 0.040 |
Why?
|
| Seizures | 1 | 2001 | 49 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2000 | 1 | 0.040 |
Why?
|
| Popliteal Vein | 1 | 2000 | 3 | 0.040 |
Why?
|
| Femoral Vein | 1 | 2000 | 13 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2020 | 8 | 0.040 |
Why?
|
| Self Administration | 1 | 2020 | 23 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 348 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 48 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 102 | 0.040 |
Why?
|
| Patient Admission | 1 | 2000 | 30 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 34 | 0.040 |
Why?
|
| Hospitalization | 2 | 2003 | 201 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 38 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2004 | 639 | 0.040 |
Why?
|
| Pain | 1 | 2001 | 258 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2000 | 98 | 0.040 |
Why?
|
| Obesity | 1 | 2005 | 705 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 373 | 0.040 |
Why?
|
| Managed Care Programs | 2 | 2012 | 16 | 0.040 |
Why?
|
| Algorithms | 1 | 2001 | 432 | 0.040 |
Why?
|
| P-Selectin | 3 | 1994 | 30 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2000 | 155 | 0.040 |
Why?
|
| Pediatrics | 1 | 2000 | 117 | 0.040 |
Why?
|
| Cellular Senescence | 3 | 1994 | 149 | 0.040 |
Why?
|
| Oncologists | 1 | 2018 | 15 | 0.040 |
Why?
|
| Fibrinogen | 2 | 1996 | 50 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1998 | 51 | 0.030 |
Why?
|
| Social Behavior | 2 | 2008 | 54 | 0.030 |
Why?
|
| Sex Distribution | 1 | 1997 | 78 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 645 | 0.030 |
Why?
|
| Dogs | 5 | 1996 | 510 | 0.030 |
Why?
|
| Acute-Phase Reaction | 1 | 1996 | 4 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 1522 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 1996 | 4 | 0.030 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1996 | 4 | 0.030 |
Why?
|
| Emergencies | 1 | 1996 | 28 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 60 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 42 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2014 | 8 | 0.030 |
Why?
|
| Alemtuzumab | 1 | 2014 | 4 | 0.030 |
Why?
|
| Levonorgestrel | 1 | 2014 | 6 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 60 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2015 | 56 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 50 | 0.030 |
Why?
|
| Device Removal | 1 | 2014 | 30 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 73 | 0.030 |
Why?
|
| Leucovorin | 1 | 2014 | 19 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 58 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2014 | 77 | 0.030 |
Why?
|
| Thrombin | 1 | 1994 | 69 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 69 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2014 | 106 | 0.020 |
Why?
|
| Endocarditis | 1 | 2013 | 20 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 285 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2013 | 63 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 62 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 86 | 0.020 |
Why?
|
| Population | 1 | 2012 | 3 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 668 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 122 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 51 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 51 | 0.020 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 13 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 116 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 35 | 0.020 |
Why?
|
| Commerce | 1 | 2012 | 61 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 645 | 0.020 |
Why?
|
| Asian Americans | 1 | 2011 | 40 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 80 | 0.020 |
Why?
|
| Temperature | 1 | 1992 | 213 | 0.020 |
Why?
|
| Methods | 1 | 2010 | 27 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 303 | 0.020 |
Why?
|
| Data Mining | 1 | 2010 | 17 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 46 | 0.020 |
Why?
|
| Hemostasis | 1 | 2010 | 48 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 55 | 0.020 |
Why?
|
| Models, Biological | 1 | 1992 | 471 | 0.020 |
Why?
|
| Flow Cytometry | 3 | 1994 | 292 | 0.020 |
Why?
|
| New York City | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2008 | 26 | 0.020 |
Why?
|
| California | 1 | 2008 | 70 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2000 | 244 | 0.020 |
Why?
|
| Focus Groups | 1 | 2008 | 105 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1009 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2008 | 91 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 431 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2008 | 135 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 46 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 128 | 0.020 |
Why?
|
| Mental Health | 1 | 2008 | 111 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 46 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 118 | 0.020 |
Why?
|
| Emotions | 1 | 2008 | 139 | 0.020 |
Why?
|
| Kidney | 1 | 2008 | 289 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 525 | 0.010 |
Why?
|
| Hemoglobinometry | 1 | 2004 | 5 | 0.010 |
Why?
|
| Fee-for-Service Plans | 1 | 2004 | 8 | 0.010 |
Why?
|
| Topotecan | 1 | 2004 | 12 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2004 | 28 | 0.010 |
Why?
|
| Cost Savings | 1 | 2004 | 20 | 0.010 |
Why?
|
| Biotin | 2 | 1994 | 25 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 69 | 0.010 |
Why?
|
| Anemia | 1 | 2004 | 43 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 211 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 237 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2003 | 38 | 0.010 |
Why?
|
| Fungemia | 1 | 2000 | 5 | 0.010 |
Why?
|
| Phlebography | 1 | 2000 | 20 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 607 | 0.010 |
Why?
|
| Oncostatin M | 1 | 1996 | 4 | 0.010 |
Why?
|
| Hybridomas | 1 | 1996 | 17 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 1996 | 31 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 1996 | 94 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 257 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 314 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1994 | 5 | 0.010 |
Why?
|
| Platelet Activating Factor | 1 | 1994 | 7 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1994 | 9 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 1994 | 27 | 0.010 |
Why?
|
| Peptides | 1 | 1996 | 297 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 697 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 1057 | 0.010 |
Why?
|